Bevacizumab in lung cancer patients generally needs to be used continuously until the lung cancer patients become resistant to bevacizumab, or there is an adverse reaction that is not tolerated by the patients, or the disease progresses, so the specific course of medication for each patient cannot be determined. Bevacizumab is an anti-angiogenic targeted drug, which is often used in combination with chemotherapeutic drugs for the treatment of advanced lung cancer. Generally, it is used in combination with chemotherapeutic drugs for 4~6 cycles, and then bevacizumab alone is used for maintenance treatment. If the treatment is effective, bevacizumab is required to be used continuously for the lung cancer patients until drug resistance, serious adverse reactions or disease progression occurs. Common side effects of bevacizumab include high blood pressure, proteinuria, bleeding, gastrointestinal adverse reactions, etc. It should be used under doctor’s guidance, and should be reviewed regularly during the period of using the drug, and consult the doctor if there is any discomfort in time, so as to avoid delaying the condition.